Literature DB >> 21310720

Anaphylactic reaction after methylene blue-treated plasma transfusion.

P Dewachter1, S Castro, P Nicaise-Roland, S Chollet-Martin, C Le Beller, A Lillo-le-Louet, C Mouton-Faivre.   

Abstract

Methylene blue-treated fresh-frozen plasma (MB-FFP) is mainly used in Europe. The advantage of the methylene blue system is that units can be treated individually. The combined action of methylene blue and illumination is a photodynamic process preventing viral RNA and DNA replication. We report the first immediate allergic hypersensitivity reaction to methylene blue-treated plasma transfusion. The clinical course and subsequent assessment of the allergic reaction, including skin tests and basophil activation test, confirmed methylene blue-induced IgE-mediated anaphylaxis. All immediate reactions after MB-FFP transfusion should be investigated to document the underlying mechanism.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21310720     DOI： 10.1093/bja/aer009

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


  7 in total

Review 1.  State-of-the-art review about basophil research in immunology and allergy: is the time right to treat these cells with the respect they deserve?

Authors:  Salvatore Chirumbolo
Journal:  Blood Transfus       Date:  2011-12-21       Impact factor: 3.443

2.  Allergic and anaphylactic reactions to methylene-blue-treated plasma in Catalonia in the period 2008-2013.

Authors:  Eduardo Muñiz-Diaz; Lluis Puig
Journal:  Blood Transfus       Date:  2014-10       Impact factor: 3.443

Review 3.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

4.  Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.

Authors:  Alfred Gugerell; Dirk Sorgenfrey; Maria Laggner; Jürgen Raimann; Anja Peterbauer; Daniel Bormann; Susanne Suessner; Christian Gabriel; Bernhard Moser; Tobias Ostler; Michael Mildner; Hendrik J Ankersmit
Journal:  Blood Transfus       Date:  2019-02-21       Impact factor: 3.443

Review 5.  Adverse effects of plasma transfusion.

Authors:  Suchitra Pandey; Girish N Vyas
Journal:  Transfusion       Date:  2012-05       Impact factor: 3.157

Review 6.  Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Authors:  Giovanni Di Minno; David Navarro; Carlo Federico Perno; Mariana Canaro; Lutz Gürtler; James W Ironside; Hermann Eichler; Andreas Tiede
Journal:  Ann Hematol       Date:  2017-06-18       Impact factor: 3.673

Review 7.  Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment.

Authors:  Fumiya Hirayama
Journal:  Br J Haematol       Date:  2012-12-06       Impact factor: 6.998
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.